92254-28-9

Basic information

• Product Name: Methyl 2'-hydroxybiphenyl-3-carboxylate
• Synonyms: Methyl 2'-hydroxybiphenyl-3-carboxylate;2-(3-Methoxycarbonylphenyl)phenol
• CAS NO: 92254-28-9
• Molecular Formula: C₁₄H₁₂O₃
• Molecular Weight: 228.24328
• Mol File: 92254-28-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 2'-hydroxybiphenyl-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2'-hydroxybiphenyl-3-carboxylate(92254-28-9)
• EPA Substance Registry System: Methyl 2'-hydroxybiphenyl-3-carboxylate(92254-28-9)

Safety Data

• Hazardous Substances Data: 92254-28-9(Hazardous Substances Data)

Usage

Description

Methyl 2'-hydroxybiphenyl-3-carboxylate is an organic compound that belongs to the class of biphenyl carboxylic acid esters. It is a derivative of biphenyl, wherein two phenyl rings are connected by a carboxyl group. The presence of a hydroxy group at the 2' position on one of the phenyl rings and the ester functional group at the 3 position of the carboxylic acid gives this compound its unique properties.
Used in Pharmaceutical Industry:
Methyl 2'-hydroxybiphenyl-3-carboxylate is used as a pharmaceutical candidate for its potential biological activity due to its structural features.
Used in Agrochemical Industry:
Methyl 2'-hydroxybiphenyl-3-carboxylate is used as a potential component in the development of new pesticides due to its unique properties.

Upstream product

• 67-56-1 methanol 
• 893736-72-6 2′-hydroxy[1,1-biphenyl]-3-carboxylic acid 
• 168618-50-6 methyl 2'-methoxy(1,1'-biphenyl)-3-carboxylate 

Downstream Products

• 171905-61-6 2'-((2R,3S,4S,5R,6R)-3,4,5-Triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-biphenyl-3-carboxylic acid methyl ester 
• 1460301-53-4 benzyl N-[(10S,12S,16S)-12-amino-20-methyl-15,21-dioxo-8-oxa-14,20-diazatetracyclo[20.3.1.0^2,7.0^10,14]hexacosa-1⁽²⁶⁾,2,4,6,22,24-hexaen-16-yl]carbamate hydrochloride 
• 1460301-54-5 benzyl N-[(10S,12S,16S)-20-methyl-12-{[2-(2-naphthyl)acetyl]amino}-15,21-dioxo-8-oxa-14,20-diazatetracyclo[20.3.1.0²'⁷.0¹⁰¹⁴]hexacosa-1⁽²⁶⁾,2,4,6,22,24-hexaen-16-yl]carbamate 
• 1460301-61-4 N-[(10S,12S,16S)-20-methyl-15,21-dioxo-16-[(2-phenylacetyl)amino]-8-oxa-14,20-diazatetracyclo[20.3.1.0²'⁷.0¹⁰'¹⁴]hexacosa-1⁽²⁶⁾,2,4,6,22,24-hexaen-12-yl]-2-(2-naphthyl)acetamide 
• 1460301-62-5 N-[(10S,12S,16S)-20-methyl-12-{[2-(2-naphthyl)acetyl]amino}-15,21-dioxo-8-oxa-14,20-diazatetracyclo[20.3.1.0²'⁷.0¹⁰¹⁴]exacosa-1⁽²⁶⁾,2,4,6,22,24-hexaen-16-yl]benzamide 
• 1460306-74-4 C₂₇H₃₂N₂O₇ 
• 1460306-75-5 C₄₄H₅₄N₄O₁₀ 
• 1460306-73-3 C₂₈H₃₄N₂O₇ 
• 1053732-17-4 (S)-3-Phenyl-2-{[2'-((3aS,4R,5aR,9aR,9bS)-2,2,8,8-tetramethyl-hexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxin-4-yloxy)-biphenyl-3-carbonyl]-amino}-propionic acid ethyl ester 
• 1054614-78-6 {[2'-((3aS,4R,5aR,9aR,9bS)-2,2,8,8-Tetramethyl-hexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxin-4-yloxy)-biphenyl-3-carbonyl]-amino}-acetic acid ethyl ester 

Relevant articles and documents

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

Compositions and methods of inhibiting the binding of E-selectin or P-selectin or sialyl-Lewisx or sialyl-Lewisa

This invention relates to compounds that inhibit the binding of E-selectin or P-selectin to sialyl-Lewisx or sialyl-Lewisa presented on a cell surface having the general structure: STR1 This invention also relates to methods of inhibiting the binding of E-selectin or P-selectin to sialyl-Lewisx or sialyl-Lewisa presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewisx and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occurs following heart attacks, strokes and organ transplants and to the treatment of cancer.